Trevi Therapeutics Inc. (TRVI)
3.90
-0.07 (-1.76%)
At close: Jan 28, 2025, 1:46 PM
undefined% (undefined)
| Bid | 3.89 |
| Market Cap | 348.53M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.44 |
| PE Ratio (ttm) | -8.86 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 3.91 |
| Volume | 259,774 |
| Avg. Volume (20D) | 1,781,669 |
| Open | 3.98 |
| Previous Close | 3.97 |
| Day's Range | 3.86 - 4.06 |
| 52-Week Range | 1.35 - 4.68 |
| Beta | undefined |
About TRVI
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo P...
Industry Biotechnology
Sector Healthcare
IPO Date May 7, 2019
Employees 27
Stock Exchange NASDAQ
Ticker Symbol TRVI
Analyst Forecast
According to 9 analyst ratings, the average rating for TRVI stock is "Buy." The 12-month stock price forecast is $7.5, which is an increase of 92.31% from the latest price.
Buy 88.89%
Hold 0.00%
Sell 0.00%
1 month ago
+15.83%
Trevi Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
1 month ago
+44.58%
Trevi Therapeutics shares are trading higher after the company announced positive outcomes for the treatment of patients from its chronic cough Phase 2b CORAL trial.
